Based on the key indicators related to Plus Therapeutics' liquidity, profitability, solvency, and operating efficiency, Plus Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, Plus Therapeutics' Short and Long Term Debt is fairly stable compared to the past year. Key indicators impacting Plus Therapeutics' financial strength include:
The essential information of the day-to-day investment outlook for Plus Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Plus Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Plus Therapeutics.
Please note, the imprecision that can be found in Plus Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Plus Therapeutics. Check Plus Therapeutics' Beneish M Score to see the likelihood of Plus Therapeutics' management manipulating its earnings.
Plus Therapeutics Stock Summary
Plus Therapeutics competes with Aditxt, Palisade Bio, Revelation Biosciences, Quoin Pharmaceuticals, and Zura Bio. Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. Plus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Plus Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Plus Therapeutics's current stock value. Our valuation model uses many indicators to compare Plus Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Plus Therapeutics competition to find correlations between indicators driving Plus Therapeutics's intrinsic value. More Info.
Plus Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Plus Therapeutics' Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Plus Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Plus Therapeutics Systematic Risk
Plus Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Plus Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Plus Therapeutics correlated with the market. If Beta is less than 0 Plus Therapeutics generally moves in the opposite direction as compared to the market. If Plus Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Plus Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Plus Therapeutics is generally in the same direction as the market. If Beta > 1 Plus Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Plus Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Plus Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Plus Therapeutics growth as a starting point in their analysis.
Plus Therapeutics March 21, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Plus Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Plus Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Plus Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Plus Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Plus Therapeutics's daily price indicators and compare them against related drivers.
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.